Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Carcinoma, Hepatocellular 6Adenocarcinoma 6Neoplasms 5Lung Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Urethral Neoplasms 3Rectal Neoplasms 3Neoplasm Metastasis 3Liver Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Ureteral Neoplasms 2Solid Tumors 2Sarcoma 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Biliary Tract Neoplasms 2Thymoma 1Solid Tumor 1Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Gemcitabine 31Cisplatin 21pembrolizumab 8Fluorouracil 6Oxaliplatin 5Capecitabine 5130-nm albumin-bound paclitaxel 5durvalumab 4Taxes 4Albumin-Bound Paclitaxel 4pemigatinib 3infigratinib 3atezolizumab 3Specimen Handling 3Radiosurgery 3Platinum 3Magnetic Resonance Spectroscopy 3Leucovorin 3Carboplatin 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3tremelimumab 2trametinib 2olaparib 2ivosidenib 2derazantinib 2cobimetinib 2Trastuzumab 2Radiotherapy 2Panitumumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cholangiocarcinoma × Ramucirumab × Clear all
NCT02520141 2023-06-15

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 2 Completed
61 enrolled 9 charts
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡